Feb 4, 2021 7:00 am EST Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium
Jan 20, 2021 7:00 am EST Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference
Jan 13, 2021 7:00 am EST Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results
Jan 4, 2021 7:00 am EST Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference
Dec 18, 2020 5:00 pm EST Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Dec 15, 2020 8:01 pm EST Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock
Dec 14, 2020 4:45 pm EST Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock
Dec 4, 2020 7:00 am EST Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma
Nov 23, 2020 5:00 pm EST Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
